Kalbitor (ecallantide)

Kalbitor (ecallantide) is covered only for acute HAE attacks in patients with HAE type I or II (excluded for prophylaxis or non‑HAE indications). Coverage requires baseline functional C1‑INH <50% and low serum C4, prescription by or in consultation with an HAE specialist (allergist/immunologist), dosing 30 mg SC with one additional 30 mg allowed within 24 hours, 12‑month approval periods, and reauthorization requires prior Kalbitor use with documented favorable clinical response.

"Kalbitor is indicated for the treatment of acute Hereditary Angioedema (HAE) attacks."

Sign up to see full coverage criteria, indications, and limitations.